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This article suggests that cell lineages of defined phenotype arise within gas-
trointestinal epithelia exposed to acid hypersecretion - the ulcer-associated
cell lineage (UACL), "gastric metaplasia" and that of Barrett's esophagus.
Detailed study of both the histogenesis and secretory peptide phenotype of the
UACL and gastric metaplasia reveal an origin from newly-formed ducts and
Brunner's gland ducts, respectively. It is suggested that Barrett's epithelium
arises directly from the epithelium of the cardiac esophageal glands, and that
these three ductal epithelia are theorigins ofthese three important adaptive phe-
nomena to gastric hypersecretion.
INTRODUCTION
Gastric acid hypersecretion is associated with a number of morphological appear-
ances: in acid reflux disease, there are changes in the oesophagus, which are usually des-
ignated as Barrett's esophagus, where the usual squamous mucosal lining becomes
replaced by columnarepithelial cells ofputative specific aspect. In the duodenum, the villi
become covered with mucus-secreting cells, which powerfully resemble the cells that line
the gastric foveolae, so much so that they are often referred to as "gastric metaplasia."
Lastly, in both the duodenum in peptic ulceration, with its associated excess secretion of
acid, and in the gastric mucosa in chronic atrophic gastritis, often associated with peptic
ulceration and Helicobacterpylori infection, there evolves a lineage that also resembles
gastric epithelium, often seen occupying the lamina propria, but also growing onto the
villi in the duodenum and replacing the indigenous surface lineages. This has, in the past,
beenreferred to "pyloric" or"pseudopyloric" metaplasia [1, 2], oreven as Brunner's gland
metaplasia because ofmorphological similarities with these cells [2]. More recently, these
structures have been given the rather pretentious, but perhaps more accurate name, ulcer-
associated cell lineage (UACL)b [3].
Thus, we have three situations where abnormal secretion of acid apparently leads to
the evolution ofthree discrete morphological states. Here we shall make the case that each
of these morphological phenomena are caused by the upward growth and migration of
ductular cells: in the case of Barrett's esophagus, the cells grow from the ducts of
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esophageal glands upwards onto the esophageal surface, while in the case ofgastric meta-
plasia ofthe duodenum, the surface cells are derived from the ductular cells ofBrunner's
glands. Thus, the stomach is confined by two structures that have the capacity to respond
morphologically to the presence ofexcess acid: proximally the esophageal glands and dis-
tally, the Brunner's glands. Where no pre-existing structures with ducts are present, then
a new gland develops, the UACL, whose ducts grow to make contact with the gut lumen
in the duodenum via a nearby villus, and cells migrate through this duct to reach and
clothe the adjacent villus [3].
Moreover, recent morphological, immunohistochemical and in situ hybridization
studies have shown that, far from being mere metaplasias, these cell lineages do, in fact,
have novel functional properties: they have a definable life history during which they
sequentially acquire differentiation antigens constituting a distinct phenotype and synthe-
size and secrete large amounts of regulatory peptides of considerable interest. In some
instances, the presence ofthese cells in the ulcerated mucosa also appears to induce pep-
tide gene expression in the local intestinal cells.
THE HISTOGENESIS OF THE ULCER-ASSOCIATED CELL LINEAGE
In the duodenum, the UACL appears first as a small, intensely D/PAS positive bud
at the base of the intestinal crypts adjacent to a peptic ulcer, and these buds push out-
wards into the surrounding stroma of the lamina propria as small tubules, which quick-
ly coalesce with tubules from other crypts to form a more or less complex acinar arrange-
ment. They also lie within adistinctive, immature,,acid mucopolysaccharide-rich stroma.
In larger gland formations, a single duct is formed by thejoining of two or more small-
er ductules, and this duct grows upwards through the core of an adjacent villus towards
the epithelial surface. At the epithelial surface, the duct emerges through a distinct pore.
The UACL moves out of the tubule and onto the villus surface, where it replaces the
_~ ~~~A 5
Figure 1. A mature complex of the ulcer-associated cell lineage, showing the basal acini, the
duct system and the cells that migrate out onto the surface to clothe it, replacing the indige-
nous cell lineages.Wright: Histogenesis ofacid-associated changes in gastrointestinal epithelia
indigenous surface cell lineages. The entire villous surface can thus become covered with
the UACL cells. Figure 1 shows a mature UACLcomplex, with the glandularportion giv-
ing rise to the duct, from whence cells migrate onto the villous surface to cover it.
In the UACL, once the duct is formed, about two-thirds of the way up the duct, a
clearly defined zone of proliferating-cell-nuclear-antigen (PCNA)-positive cells appears
in which mitotic figures can also sometimes be seen. This zone is quite discrete and ends
well before the duct emerges onto the surface. Thus, the important duct area in this lin-
eage is also the site of the proliferative zone [4]. It is interesting and relevant that
Brunner's gland primordia also begin as small buds that grow out of the duodenal crypts
at about 16 weeks ofintrauterine life in the human, grow as tubules in the submucosa and
by 36 weeks achieve the familiar adult tubuloalveolar pattern [4]. Thus, the histogenesis
ofthe duct in the UACL is similar to that ofBrunner's gland duct in embryonic develop-
ment. In practical terms, it means that ductular cells are available to migrate onto the sur-
face, even where Brunner's gland ducts are not available.
The UACL also expresses similar secretory proteins to the ones we have seen in the
lineages discussed above; again there is a very distinctive pattern of synthesis within the
organized structure. The acinar portion contains abundant immunoreactive epidermal
growth factor/urogastrone (EGF/URO), which is also seen in the secretions [5]. In normal
conditions, EGF/URO is produced by gut-associated salivary, esophageal and Brunner's
glands, but not by other cell lineages in the gut [6]. The location ofEGF/URO receptors
(EGFR) in gastrointestinal cells is currently under dispute. There is evidence that EGFR
in the gut are polarized to the laterobasal membranes in the rat [7], but Thompson [8] has
shown apically-sited EGFRin the neonate. However, these EGFreceptors on the microvil-
lar membrane are apparently not associated with phosphorylation of membrane proteins
after ligand:receptor binding [9]. Radiolabeled EGF/URO given orally to normal rats does
not bind to the intact mucosa but readily binds locally when a mucosal defect is present
[10]. Moreover, EGF/URO has been reported to be mitogenically active parenterally but
not when given directly into the intestine [11], although this too has been disputed [12].
Whatever the exact binding mechanism, the secretion ofEGF/URO by the UACL ensures
that the peptide is available locally to stimulate repair and regeneration in the local ulcer
environment, and we have suggested that this is an important in vivo role for EGF/URO
[5].
Other regulatory peptide genes are also expressed by the UACL in a site-specific
manner. hSP and pS2 are members of the trefoil peptide family, a growing group of pro-
teins that share the unique "trefoil" motif, a three-leafed domain held by disulfide bonds
based on cysteine residues [13]. The canonical molecule is pS2, a 60 amino acid secreto-
ry protein that was originally found by differentially screening a cDNA library from the
human breast carcinoma cell line MCF-7 [14]. The function ofpS2 is as yet unknown, but
it is highly homologous with spasmolytic polypeptide, a known gastrointestinal regulato-
ry peptide, in which the trefoil domain is tandomly repeated [15]. It has been claimed that
porcine spasmolytic polypeptide inhibits gastric acid secretion and also intestinal motili-
ty [16, 17] and is mitogenic for MCF-7 and colorectal carcinoma cells in vitro [18], and
ligand:receptor binding results in inhibition of adenylate cyclase [16]. However, these
claims have now been disputed, and the trefoil peptides are now regarded as important
motogens for gastrointestinal epithelial cells (see Poulsom in this issue [page 137]). In the
normal stomach, pS2 and hSP are secreted and are co-expressed by the foveolar and sur-
face cells [19], although they are products of different genes [20]. Moreover, hSP is
expressed in large amounts in the pyloric glands of the gastric antrum and in Brunner's
gland acini. hSP and pS2 mRNA expression can be readily demonstrated by hybridization
in situ using35S labeledriboprobes. hSP mRNA is found in the acini and lower ductcells,
whereas pS2 mRNA and protein are localized in large amounts in the upper duct and all
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surface cells. Moreover, it has recently been shown that the UACL expresses a third mem-
ber ofthe trefoil peptide family, intestinal trefoil factor (ITF), a single trefoil domain pep-
tide [9], constitutively expressed by intestinal goblet cell, but not by gastric mucous cells
[21]. ITF is expressed throughout the UACL. Addition ofrecombinant rat ITF to the baso-
lateral surface of rat small intestine results in an increase in short-circuit current, associ-
ated with increased chloride secretion, and binding sites, have been demonstrated on the
surface of the rat small intestinal mucosa [21]. These peptides also have powerful moto-
genic properties [18a]. Thus, the UACL secretes at least four peptides with potentially
important biological effects. A further protein of significance is produced by the UACL:
lysozyme, which has antibacterial and putative immunoregulatory function. Both
lysozyme mRNA and protein are found in abundance in the UACL [10].
In addition, it is becoming clear that the UACL is also associated with trefoil peptide
gene expression in the indigenous cell lineages in the adjacent mucosa [22]. The normal
cell lineages in the intestine include the mucin-producing goblet cells, neuroendocrine
cells and enterocytes. The mucous cells in the vicinity of the UACL express abundant
immunoreactive pS2 in the basal parts ofthe cytoplasm in formalin-fixed paraffin-embed-
ded sections. In glutaraldehyde-fixed, resin-embedded sections, in addition to labeling in
the Golgi area, pS2 is seen within the theca also. In situ hybridization with an 35S-labeled
antisense riboprobe shows pS2 mRNA localized in considerable concentration in the cyto-
plasm beneath the mucus-filled theca. Ultrastructural immunocytochemistry confirms that
immunoreactive pS2 is found in the rough endoplasmic reticulum ofthese cells and is also
co-packaged via the Golgi complex into the mucous granules. Thus, the mucous cells
adjacent to peptic ulcers where the UACL is seen show pS2 expression and also co-secrete
pS2 with the liberated mucus into the intestinal lumen. In addition, neuroendocrine cells
adjacent to the UACL also express pS2 protein [22]. The finding ofthe same peptide co-
packaged in both mucous granules and neuroendocrine granules is highly unusual:
mucous granules are secreted into the lumen, whereas neuroendocrine granules are
released into the basal and lateral membranes. The function of these granules are, of
course, very different. Mucus has lubricating and protective functions in the gut, but
endocrine secretions release various regulatory peptides that act viaparacrine or autocrine
mechanisms to produce manifold effects on the gut [23].
The pattern of peptide expression in the UACL also points to its histogenesis:
Brunner's gland primordia begin as bud-like outgrowths from the bases of duodenal
crypts, which form tubules that by 28 weeks of intrauterine life show the familiar tubu-
loalveolarpattern ofthe adult Brunner's glands. At 18 weeks, immunoreactive EGF/URO
is present in abundance, while pS2 peptide is confined to the developing ducts. However,
hSP mRNA is present in considerable concentration throughout Brunner's gland acini and
ducts. This pattern oftrefoil gene expression is maintained throughout fetal life, and more-
over, in the adult, pS2 peptide and transcripts are expressed by the ductal cells, and large
amounts of hSP protein and mRNA are present in the acini [4, 10]. These observations
indicate that the UACL reiterates the developmental program ofBrunner's glands.
These observations indicate that the UACL is not a metaplasia, which formally can
be defined as a change from one defined differentiated phenotype to another. The UACL,
though sharing several phenotypic features with other cell lineages in the gut, does have
a unique structure and function. Since it is induced only in chronic ulcerative conditions,
it would certainly appear to be a primary defense reaction, producing a cocktail of active
peptides and proteins, EGF/URO, hSP, pS2 and lysozyme, which would be expected to
advance mucosal healing. There are also early indications that other peptides may be pro-
duced by the UACL, and immunoreactive TGF-a has been detected.Wright: Histogenesis ofacid-associated changes in gastrointestinal epithelia
THE HISTOGENESIS OF DUODENAL GASTRIC METAPLASIA
In duodenitis and duodenal ulcerdisease, cells with the apparent phenotype ofgastric
foveolar epithelial cells appear on the surface of duodenal villi. These have been called
gastric metaplasia with the implication that these cells arise by ametaplastic process from
villus epithelial cells, or more believably, from the duodenal crypt cells. This is despite
numerous studies, both by ourselves [24] and others, which show fairly unequivocally that
these cells arise in continuity with Brunner's gland ducts. It is well known that Brunner's
gland acini contain immunoreactive EGF (and also hSP mRNA and peptide), and recent
studies have also drawn parallels between the trefoil peptide status ofthe ductal epitheli-
um and of the gastric metaplastic epithelium; they both contain pS2 and hSP mRNA and
pS2 peptides, although hSP peptides not always demonstrable. The presence of EGF in
the acini, and trefoil peptide gene expression in the duct is, ofcourse, not dissimilar to the
UACL, although the topography differs. The Brunner's gland duct epithelium is thus con-
sidered to be the source ofgastric metaplasia.
THE HISTOGENESIS OF BARRETT'S ESOPHAGUS
The distal esophagus is lined by squamous epithelium, which, when exposed to
chronic reflux ofgastroduodenal contents, is sometimes replaced by the glandular epithe-
lium ofBarrett's esophagus. There are usually three types ofepithelium that line Barrett's
oesophagus: rather atrophic fundic mucosa, mucosa with complete or type 1 intestinal
metaplasia and so-called specialized Barrett's epithelium, resembling the incomplete or
type 2 intestinal metaplasiaofthe stomach. Itis usually assumed that suchepithelium aris-
es from ingrowth by the cardiac epithelium, which grows in to cover the ulcerated and
largely destroyed squamous epithelium. However, there are several observations that are
not in accord with this concept: when the esophageal mucosa of experimental animals is
stripped and there is no continuity between the gastric epithelium and the proximal
esophageal squamous epithelium, islands of mucin-secreting epithelium appear in the
ulcerated area. Similarly, when patients with established Barrett's esophagus are treated
with powerful antisecretory therapy such as omeprazole, the proton pump inhibitor,
islands of squamous epithelium appear in the glandular epithelium. These observations
suggest, not that gastric mucosa grows in from the cardia, or that squamous epithelium
grows in to repair the defect from above, but that a stem cell population is present, which
gives rise to Barrett's epithelium independently of the gastric mucosa, and conversely,
these stem cells remain beneath the Barrett's epithelium to regenerate the squamous
epithelium in the repair process. The candidate population of stem cells here is the ducts
of the subjacent esophageal glands, which remain under the mucosa, even in Barrett's
esophagus.
Classically, there are two types of glands to be found in the esophageal mucosa:
esophageal glands proper and the esophageal cardiac glands. The former are small, com-
pound glands with richly-branched tubulo-alveolar secretory portions containing only
mucous cells; the ducts are lined by low columnar epithelium in the lower part, and more
superficially, with stratified squamous epithelium. The esophageal cardiac glands are
found both in thepost-cricoid area and in theloweroesophagus and are located in the lam-
inapropria. The branched tubules contain cells with granular and mucous cytoplasm. The
small ducts, lined with cuboidal epithelium, fuse into a larger, duct, lined with columnar
epithelium, which "more or less resembles the mucous epithelium ofthe gastric foveolae"
(Figure 2). It is these gland ducts that are the candidate source ofBarrett's esophagus.
There has been little work on the secretory phenotype ofthe esophageal glands. There
is also evidence that theesophagealglands secreteesophageal EGF. There has been no sys-
tematic study ofthe other secretory peptides made by these glands. There is trefoil peptide
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Figure 2. A diagram ofa submucosal esophageal gland, showing the gland duct piercing the
stratified squamous epithelium and the muscularis mucosae to reach the acini in the submu-
cosa.
gene expression in the epithelium of Barrett's' esophagus. Both hSP and pS2 mRNA was
present in the superficial epithelium, although hSP peptides could not always be demon-
strated. The deeper epithelium contained only hSP and its message. Thus, an interesting
parallel emerges between this epithelium and that of gastric metaplasia: the superficial
epithelium contains pS2 and hSP, while hSP and EGF are present in the deeper glands.
While this may merely mean similar adaptation to an acid-rich environment, a reasonable
hypothesis, which will stand falsification, is that the esophageal gland ducts are the origin
of the Barrett's epithelium, as Brunner's gland ducts are the origin of gastric metaplasia
and the UACL duct is the origin ofthe UACL surface lineage. Thus, we can draw a paral-
lel between the rather neglected epithelium of these three ducts: they are of undoubted
importance in the histogenesis of gastrointestinal adaptations to gastric acid hypersecre-
tion.
CONCLUSION
It is clear from this discussion that the cells that line the ducts of gut-associated
glands are remarkably plastic and, arguably, are able to give rise to a number ofimportant
cell lineages in gastrointestinal pathology. The means are available to explore the geno-
type of the respective lineages and to assess whether these proposals are appropriate.
REFERENCES
1. Kawel, C.A. andTesluk, H. Brunner-type glands in regional enteritis. Gastroenterology 28:210-
221, 1955.
2. Lee, F. Pyloric metaplasia in the small intestine. J. Pathol. Bact. 87:257-279, 1964.
3. Wright, N.A., Elia, G., and Pike, C. Ulceration induces a novel epidermal growth factor-secret-
ing cell lineage in the human gastrointestinal mucosa. Digestion 46(Suppl. 2):125-133, 1990.
4. Ahnen, D.J., Poulsom, R., Stamp, G.W.H., Elia, G., Pike, C., Jeffery, R.E., Longcroft, J.M., Rio,
M-C., Chambon, P., and Wright, N.A. The ulceration associated cell lineage (UACL) reiterates
the Brunner's gland differentiation program but acquires the proliferative organisation of the
gastric gland. J. Pathol. 173:317-326, 1994.Wright: Histogenesis ofacid-associated changes in gastrointestinal epithelia 153
5. Wright, N.A., Pike, C., and Elia, G. Induction of a novel epidermal growth factor-secreting cell
lineage by mucosal ulceration in gastrointestinal stem cells. Nature 343:82-85, 1990.
6. Heitz, P., Kasper, M., Van Noorden, S., Polak J.M., Gregory, H., and Pearse, A.G.E. Immuno-
histochemical localisation of urogastrone to human duodenal and submandibular glands. Gut
19:408-413, 1978.
7. Scheving, L.A., Shuirka, R.A., Nguyen, T.D., and Gray, G.M. Epidermal growth factor receptor
in the intestinal enterocyte. Localisation to laterobasal but not brush border membranes. J. Biol.
Chem. 264:1735-1741, 1989.
8. Thompson, J.F. Specific receptors for epidermal growth factor on rat intestinal microvillus
membranes. Am. J. Physiol. 254:429-435, 1988.
9. Kelly, D., McFadyen, M., Morgan, C., and King, T.P. Growth factors in colostrum: receptor
localisation and stimulation of phosphorylation in microvillar membranes of neonatal pigs. J.
Physiol. 56:38, 1992
10. Wright, N.A., Poulsom, R., Stamp, G.W.H., Hall, P.A., Jeffery, R.E., Longcroft, J.M., Rio, M-
C., Tomasetto, C., and Chambon, P. Epidermal growth factor (EGF/URO) induces expression of
regulatory peptides in damaged human gastrointestinal tissues. J. Pathol. 162:279-284, 1990
11. Goodlad, R.A., Savage, A.P., Lenton, W., Gregory, H., MacCullagh, K., Bloom, S.R., and
Wright, N.A. Does urogastrone/EGF infusion have a synergistic effect on the intestine of par-
enterally-fed rats subject to small bowel resection? Clin. Sci. 75:121-126, 1988.
12. Ulshen, M.H., Lyn-Cook, L.E., and Raasch, R.A. Effects ofintraluminal epidermal growth fac-
tor on the small intestine of young rats. Gastroenterology 254:429-435, 1986.
13. Carr, M.D. 'H NMR-based determination ofthe secondary structure ofporcine pancreatic spas-
molytic polypeptide: one of a new family of "trefoil" motif containing cell growth factors.
Biochem. 31:1998-2004, 1992.
14. Masiakowski, P., Breathnach, R., Block, J., Gannon, F., Krust, A., and Chambon, P. Cloning of
cDNA sequences ofhormone-related genes from the MCF-7 cancer cell line. Nucl. Acids Res.
10:7895-7903, 1982.
15. Jorgensen, K.H., Thim, L., and Jacobsen, H.E. Pancreatic spasmolytic polypeptide 1.
Preparation and initial chemical characterisation of a new polypeptide from porcine pancreas.
Regul. Peptides 3:207-213, 1982.
16. Frandsen, E.K., Jorgensen, K.H., and Thim, L. Receptor binding of pancreatic spasmolytic
polypeptide in rat intestinal mucosal cell membranes inhibits adenylate cyclase activity. Regul.
Peptides 16:291-29, 1986.
17. Frandsen, F.K. Receptor binding of pancreatic spasmolytic polypeptide in intestinal mucosal
cells and membranes. Regul. Peptides 20:645-652, 1988.
18. Hoosein, W.M., Thim, L., Jorgensen, K.H., and Brattain, M.G. Growth stimulatory effects of
pancreatic spasmolytic polypeptide on cultured colon and breast tumour cells. FEBS Lett.
247:303-306, 1989.
19. Rio, M-C., Bellocq, J-P., Daniel, J.U., Tomasetto, C., Lathe, R., Chenard, M.P., Batzenshlager,
A., and Chambon, P. Breast cancer-associated pS2 protein: synthesis and secretion by normal
stomach mucosa. Science 50:3532-3037, 1988.
20. Tomasetto, C., Rio, M-C., Gautier, C., Wolf, C., Hareuven, M., Chambon, P., and Lathe, R. hSP,
the domain-duplicated homologue ofpS2 protein, is co-expressed with pS2 in stomach but not
in breast carcinoma. EMBO J. 9:407-414, 1990.
21. Chinery, R., Poulsom, R., Jeffrey, R.E., Longcroft, J.M., Hanby, A., and Wright, N.A.
Localisation ofintestinal trefoil factor by in situ hybridisation. Biochem. J. 285:5-8, 1992.
22. Wright, N.A., Poulsom, R., Stamp, G.W.H., Sarraf, C., Ahnen, D., Jeffery, R., Longcroft, J.,
Elia, G., Pike, C., Rio, M-C., and Chambon, P. Trefoil peptide gene expression in inflammato-
ry bowel disease. Gastroenterol. 104:12-20, 1993.
23. Bloom, S.R. and Polak, J.P., eds. Gut Hormones. Edinburgh: Churchill Livingstone; 1981.
24. Wright, N.A. The ulcer-associated cell lineage; a newly recognised pathway of gastrointestinal
differentiation of importance in the natural healing of peptic ulcer disease. In: Helicobacter
pylori; basic mechanisms to clinical cure. Eds. R.H. Hunt and G.N. Tytgat. London: Kluwer
Academic Publisher; 1996, pp. 390-404.